Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2003
10/23/2003WO2003087317A2 Methods for targeting quadruplex dna
10/23/2003WO2003087312A2 Inhibition of tumor growth via peroxiredoxin 3
10/23/2003WO2003087308A2 Use of interleukin-24 to treat ovarian cancer
10/23/2003WO2003087307A2 Use of interleukin-19 to treat cervical cancer
10/23/2003WO2003087298A2 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
10/23/2003WO2003087197A1 Hydrogel with controllable mechanical chemical and biological properties and method for making same
10/23/2003WO2003087196A1 Thermogelling oligopeptide polymers
10/23/2003WO2003087195A2 Heterogeneous protein networks crosslinked with silicone-containing links, and methods for producing them
10/23/2003WO2003087161A1 Modified factor viii
10/23/2003WO2003087160A1 Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells
10/23/2003WO2003087159A2 Modulators of the notch signalling pathway and uses thereof in medical treatment
10/23/2003WO2003087158A2 Regulation of human transient receptor potential channel
10/23/2003WO2003087157A2 Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same
10/23/2003WO2003087156A2 Heterogeneous crosslinked protein networks and methods for producing them
10/23/2003WO2003087154A2 Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
10/23/2003WO2003087151A1 A sperm polypeptide
10/23/2003WO2003087147A1 Stretptococcal genes involved in osmotic and oxidative stress and in virulence
10/23/2003WO2003087146A2 Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism
10/23/2003WO2003087144A2 Insecticide proteins from photorabdus luminescens
10/23/2003WO2003087143A2 Human polypeptides having antibacterial activity
10/23/2003WO2003087139A2 Treatment of gastroparesis
10/23/2003WO2003087137A2 New therapeutic uses of tri-, tetra-, penta-, and polypeptides
10/23/2003WO2003087135A2 Novel pheromone receptor
10/23/2003WO2003087134A2 G-protein coupled receptor ligands and methods
10/23/2003WO2003087126A2 Heteroclitic analogs and related methods
10/23/2003WO2003087122A2 Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
10/23/2003WO2003087115A2 Oligomeric compounds having modified phosphate groups
10/23/2003WO2003087092A2 Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
10/23/2003WO2003087070A2 Growth hormone secretagogues
10/23/2003WO2003087069A2 Dipeptidic growth hormone secretagogues
10/23/2003WO2003087065A1 Inhibitors of glycinamide ribonucleotide transformylase
10/23/2003WO2003087050A2 Novel perindopril salt and pharmaceutical compositions containing same
10/23/2003WO2003086516A1 Therapeutic dry powder preparation
10/23/2003WO2003086494A1 Storage stable liquid sealer protein complex
10/23/2003WO2003086491A2 Tissue defect dressings comprising a keratin network
10/23/2003WO2003086475A1 Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
10/23/2003WO2003086470A2 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/23/2003WO2003086462A1 c-Jun PHOSPHORYLATION INHIBITORS
10/23/2003WO2003086461A2 Use of substances for treating tumors
10/23/2003WO2003086459A1 Methods of treatement using ctla-4 antibodies
10/23/2003WO2003086455A1 Immunoadjuvant
10/23/2003WO2003086452A2 Methods of enhancing lysosomal storage disease therapy
10/23/2003WO2003086450A1 Active antiangiogenic therapy
10/23/2003WO2003086449A1 ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4
10/23/2003WO2003086448A1 Use of c5a receptor antagonist in the treatment of fibrosis
10/23/2003WO2003086447A1 Methods for modulating neovascularization
10/23/2003WO2003086444A1 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
10/23/2003WO2003086421A1 External preparations for enhancing cell activity
10/23/2003WO2003086416A1 Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof
10/23/2003WO2003086374A1 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
10/23/2003WO2003086351A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003WO2003086326A2 G-type peptides to ameliorate atherosclerosis
10/23/2003WO2003086323A2 Compositions and methods for immunomodulation
10/23/2003WO2003086320A2 Use of resistin to treat hematopoietic disorders
10/23/2003WO2003086317A2 Protein a compositions and methods of use
10/23/2003WO2003086313A2 Methods for lightening skin and hair
10/23/2003WO2003086312A2 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
10/23/2003WO2003086311A2 Methods for treating tweak-related conditions
10/23/2003WO2003086308A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
10/23/2003WO2003086307A2 β2-MICROGLOBILIN (β2m) AND ANTI-β2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS
10/23/2003WO2003086298A2 Use of interleukin-19 to treat ovarian cancer
10/23/2003WO2003086296A2 Treatment for type 1 diabetes before and after expression of predisposition markers.
10/23/2003WO2003086286A2 Treatment of type 1 diabetes before and after expression of predisposition markers
10/23/2003WO2003086284A2 Colon tumor specific binding peptides
10/23/2003WO2003086280A2 Immunostimulatory g,u-containing oligoribonucleotides
10/23/2003WO2003086278A2 Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
10/23/2003WO2003086272A2 Ultrapure transferrin for pharmaceutical compositions
10/23/2003WO2003086178A2 Methods for inhibiting vascular hyperpermeability
10/23/2003WO2003086175A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/23/2003WO2003086097A1 Composition for modulating a physiological reaction or inducing an immune response
10/23/2003WO2003086093A1 Cheese capable of disinfecting helicobacter pylori
10/23/2003WO2003086078A1 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
10/23/2003WO2003065972A3 Methods for screening osteogenic compounds
10/23/2003WO2003062373A9 Methods and materials for the recruitment of endothelial cells
10/23/2003WO2003059250A3 Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
10/23/2003WO2003057898A3 Methods and materials for modulating p2x2
10/23/2003WO2003057865A8 Composition and method of creating, regenerating and repairing tissues using a cell-carrying biological implant which is enriched with a platelet concentrate and supplements
10/23/2003WO2003057714A3 A method of developing an anti-protein and regulation of a cellular function by administering an effective amount of the anti-protein
10/23/2003WO2003054193A3 Raf/ras binding compounds
10/23/2003WO2003054005A3 Bone polypeptide-1
10/23/2003WO2003053362A3 Systems and methods for treating patients with collagen-rich material extracted from adipose tissue
10/23/2003WO2003053325A3 Microencapsulation of drugs by solvent exchange
10/23/2003WO2003047619A3 Adjuvanted antigenic meningococcal compositions
10/23/2003WO2003047518A3 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
10/23/2003WO2003045523A3 Therapeutic coating for an intravascular implant
10/23/2003WO2003040164A3 Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
10/23/2003WO2003033663A3 Rankl mimics and uses thereof
10/23/2003WO2003032902A3 Tumor targeted photodiagnostic-phototherapeutic agents
10/23/2003WO2003031466A3 Angiotensin peptide-carrier conjugates and uses thereof
10/23/2003WO2003030825A3 CCAAT/ENHANCER BINDING PROTEIN-β (C/EBPβ IS A MOLECULAR TARGET FOR CANCER TREATMENT
10/23/2003WO2003029410A3 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
10/23/2003WO2003025135A3 Genes associated with malignant neoplasms
10/23/2003WO2003025130A3 Receptors and membrane-associated proteins
10/23/2003WO2003022255A3 Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
10/23/2003WO2003016466A3 ANTI-Aβ ANTIBODIES
10/23/2003WO2003014307A3 Antisense modulation of apolipoprotein(a) expression
10/23/2003WO2003011908A3 Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof
10/23/2003WO2003010201A3 Blood group antigen fusion polypeptides and methods of use thereof
10/23/2003WO2003008576A3 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
10/23/2003WO2003008543A3 Antisense modulation of bcl2-associated x protein expression
1 ... 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 ... 3163